Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
July 31, 2023 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced it has begun dosing the second dose-escalation cohort in its pivotal Phase 1/2/3...
Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update
July 27, 2023 17:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 18, 2023 17:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy
July 12, 2023 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
July 06, 2023 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
Pivotal Phase 3 portion of Orbit study now enrolling approximately 195 pediatric and young adult patients Newly initiated Phase 3 Cosmic study now enrolling approximately 65 younger pediatric...
Ultragenyx Opens New Gene Therapy Manufacturing Facility in Bedford, Continuing its Expansion in Massachusetts
June 21, 2023 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
BEDFORD, Mass., June 21, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 20, 2023 17:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
June 07, 2023 17:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)
June 05, 2023 16:00 ET
|
Ultragenyx Pharmaceutical Inc.
Pediatric data show substantial induction of bone production in 1 week and a large increase in bone formation within 3 months of initiating monthly setrusumab treatment Phase 3 sites beginning to...
Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit
May 19, 2023 08:30 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...